FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.
D016049:Didanosine / Q000009:adverse effects* / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D014481:United States; D014486:United States Food and Drug Administration; D000099227:Abacavir
D016049:Didanosine; D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir